论文部分内容阅读
选择我院收治老年脑卒中合并肺部感染的患者102例,将102例患者随机分成对照组和观察组各51例,两组患者均给予脑卒中的常规治疗,对照组患者通过抗生素治疗,观察组同时静脉滴注痰热清注射液,观察对比两组患者咳嗽、发热、肺部啰音的消失时间、治疗期间及疗程结束后两组治疗有效率。结果显示卒中后出血、慢性疾病以及侵入操作是老年脑卒中患者并发肺部感染的高危因素;观察组患者在咳嗽、发热、肺部啰音的消失时间方面显著短于对照组,两组比较差异显著(P<0.05),具有统计学意义;治疗期间两组患者均未见明显的不良反应,疗程结束后观察组的治疗有效率为94.1%,显著高于对照组的76.5%,两组比较差异显著(P<0.05),具有统计学意义。对于存在容易引发肺部感染危险因素的脑卒中患者,应该及时展开预防处理,从而降低肺部感染的发生率;抗菌治疗的基础上联合注痰热清注射液治疗老年脑卒中患者并发肺部感染能够促进症状的改善缓解,疗效确切且安全有效,值得临床推广。
A total of 102 elderly patients with stroke and pulmonary infection were enrolled in this study. 102 patients were randomly divided into control group and observation group (n = 51). Both groups were given routine treatment of stroke, and patients in the control group were treated with antibiotics. At the same time intravenous infusion of Tanreqing injection, observed and compared two groups of patients cough, fever, pulmonary rales disappear time, during and after treatment, the two groups of treatment efficiency. The results showed that post-stroke bleeding, chronic diseases and invasive procedures were risk factors for elderly patients with stroke complicated by pulmonary infection. Patients in the observation group were significantly shorter in cough, fever, and disappearance of pulmonary rales compared with the control group, showing significant differences between the two groups (P0.05) .There was no significant adverse reaction between the two groups during the treatment. After the treatment, the treatment efficiency of the observation group was 94.1%, which was significantly higher than 76.5% of the control group The difference was significant (P <0.05), with statistical significance. For those stroke patients who are at risk of causing pulmonary infection, timely prevention and treatment should be carried out to reduce the incidence of pulmonary infection. On the basis of antibacterial therapy, combined with Tanreqing Injection for the treatment of senile stroke patients complicated by pulmonary infection Can improve the relief of symptoms, effective and safe and effective, worthy of clinical promotion.